- NurExone Biologic (NRX) has completed its securities-for-debt settlement
- NurExone agreed to settle debts in the amount of C$46,523.69 by issuing 122,430 common shares at $0.38 per share
- These debts were incurred before the recent reverse takeover transaction
- NurExone Biologic Inc. is a pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered non-invasively to patients who have suffered traumatic spinal cord injuries
- NurExone Biologic Inc. opened trading at $0.39
NurExone Biologic (NRX) has completed its securities-for-debt settlement.
The company had previously announced the securities-for-debt settlement on November 24, 2022.
NurExone agreed to settle debts in the amount of C$46,523.69 by issuing 122,430 common shares at $0.38 per share.
These debts were incurred prior to the recent reverse takeover transaction, following which NurExone began trading under the new name “NurExone Biologic Inc.” with the trading symbol NRX.
The common shares issued will be subject to a statutory four-month hold period.
NurExone Biologic Inc. is a pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered non-invasively to patients who have suffered traumatic spinal cord injuries.
ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology.
NurExone is transferring the treatment to humans, and the company holds an exclusive worldwide licence from the Technion for the development and commercialization of the technology.
NurExone Biologic Inc. opened trading at $0.39.
